Cardiome To Present At Oppenheimer Healthcare Conference
02 Novembro 2009 - 5:35PM
PR Newswire (US)
NASDAQ: CRME TSX: COM VANCOUVER, Nov. 2 /PRNewswire-FirstCall/ --
Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM)
today announced that Doug Janzen, President and CEO, is scheduled
to present an overview of Cardiome at the Oppenheimer 20th Annual
Healthcare Conference in New York City on Wednesday, November 4,
2009 at 2:45pm Eastern (11:45am Pacific). A live webcast of Mr.
Janzen's presentation can be accessed on Cardiome's website at
http://www.cardiome.com/. A replay of the webcast will be posted
after the presentation and will be available until December 4,
2009. About Cardiome Pharma Corp. Cardiome Pharma Corp. is a
product-focused drug development company dedicated to the
advancement and commercialization of novel treatments for disorders
of the heart and circulatory system. Cardiome is traded on the
NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM).
For more information, please visit our web site at
http://www.cardiome.com/. Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments expressed or implied by such forward-looking
statements or information. Such factors include, among others, our
stage of development, lack of product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully
develop and obtain regulatory approval for vernakalant (iv) or
vernakalant (oral) in the treatment of atrial fibrillation or any
other current or future products in our targeted indications; our
future operating results are uncertain and likely to fluctuate; we
may not be able to raise additional capital; we may not be
successful in establishing additional corporate collaborations or
licensing arrangements; we may not be able to establish marketing
and sales capabilities and the costs of launching our products may
be greater than anticipated; we rely on third parties for the
continued supply and manufacture of vernakalant (iv) and
vernakalant (oral) and we have no experience in commercial
manufacturing; we may face unknown risks related to intellectual
property matters; we face increased competition from pharmaceutical
and biotechnology companies; and other factors as described in
detail in our filings with the Securities and Exchange Commission
available at http://www.sec.gov/ and the Canadian securities
regulatory authorities at http://www.sedar.com/. Given these risks
and uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by
law. DATASOURCE: Cardiome Pharma Corp. CONTACT: Peter K. Hofman,
Senior Director, Investor Relations, (604) 676-6993 or Toll Free:
1-800-330-9928, Email:
Copyright